The isolation of individual enantiomers of drugs is an important subject of interest in the pharmaceutical and medical fields, because stereochemistry can have a significant effect on the biological activity of the drug. Therefore, it is important to develop enantiomeric separation methods for the determination of the optical purity of drugs, since the undesired enantiomer is regarded as one of the impurities. The available single isomer anionic cyclodextrins (CD) can resolve the enantiomers of only a few weakly acidic analytes. To rectify this problem, the chloride salts of heptakis(6-deoxy-6-morpholinio)-cyclomaltoheptaose (HMBCD), and mono(6- deoxy-6-N,N,N r,N r,N r-pentamethylethylenediammonio)-cyclomaltoheptaose (PEMEDA-BCD), the first members of the permanently charged, single-isomer cationic cyclodextrin family, have been synthesized. The purity of process intermediates and final products was determined by HPLC-ELSD and indirect UV-detection capillary electrophoresis. Structural identity was verified by 1D and 2D NMR and massBoth cationic CD derivatives have been used for the separation of the enantiomers of strong acid, weak acid, weak base, ampholytic, and neutral analytes by capillary electrophoresis. Because the charge state of these cationic chiral resolving agents is independent of the pH of the buffer, separation could be performed in both low and high pH buffers without compromising the charge density of the resolving agent. Contrary to expectation, the multiply charged HMBCD showed poor complexation with the newly synthesized strong electrolyte test analytes. The weak binding between the analytes and HMBCD resulted in separation of enantiomers of only three strong electrolyte analytes. Strong complexation was observed between PEMEDA-BCD and the anionic and nonionic analytes in both low and high pH buffers, though complexation was stronger in the high pH buffer. Due to strong complexation between the anions and PEMEDA-BCD, only low concentrations of the resolving agent were required to effect good enantiomer resolutions. spectrometry.

No description available.

No description available.

No description available.

Local transcutaneous delivery of non-steroidal anti-inflammatory drugs avoids gastrointestinal side effects and concentrates drugs in the intended tissues. An extraction and HPLC method was developed for ketoprofen in skin, fascia and muscle. Tissue samples were homogenized in NaHCO3. After methylene chloride removal of lipids, the aqueous layer was acidified with HCl and back extracted into isooctane/isopropanol. Ketoprofen was derivatized with ethylchloroformate/S-(-)-α-phenylethylamine in triethylamine, then detected by HPLC. Ketoprofen recovery was linear (1-33 μg/g) and was detected in these tissues following in vivo cathodic iontophoresis (160 mA*min). This represents the first non-radioactive method for determination of ketoprofen in tissues following transcutaneous iontophoresis.

No description available.

Organic solvent nanofiltration (OSN) is a low-energy alternative for continuous separations in the chemical industry. As the pharmaceutical sector increasingly turns toward continuous manufacturing, OSN could become a sustainable solution for chiral separations. Here we present the first comprehensive theoretical assessment of enantioselective OSN processes. Lumped dynamic models were developed for various system configurations, including structurally diverse nanofiltration cascades and single-stage separations with side-stream recycling and in situ racemization. Enantiomer excess and recovery characteristics of the different processes were assessed in terms of the solute rejection values of the enantiomer pairs. The general feasibility of stereochemical resolution using OSN processes is discussed in detail. Fundamental connections between rejection selectivity, permeance selectivity, and enantiomer excess limitations are revealed. Quantitative process performance examples are presented based on theoretical rejection scenarios and cases from the literature on chiral membranes. A model-based prediction tool can be found on www.osndatabase.com to aid researchers in connecting materials development results with early-stage process performance assessments.

The binding mechanisms of molecules to cyclodextrins continues to be studied to better explain the interactions occurring. The majority of published models focus on one-to-one molecular binding thermodynamics to explain experimental results. They rely on physical concepts of energies and forces to guide the actions of molecules expressed mathematically in terms of differential and non-linear equations. These models are limited in scope due to their complexity and are not easily expanded to study many diverse analytes. Conversely, cellular automata uses simple mathematical idealizations of systems governed by deterministic and probabilistic rules that are easily adaptable to many types of molecular interactions. The primary goal of this research is to develop a model that is easy to use in the prediction of beta-cyclodextrin chromatographic separations of enantiomers. The model uses variegated square cells to simulate the physical environment of the molecules involved, evolving by a series of discrete time-steps referred to as iterations. Governing probabilistic rules define the physical and chemical interactions. Rules are randomly applied to all the cells of the system during each iteration and the system is updated accordingly. Micro and macro visual analysis is possible in addition to statistical output. Results demonstrate the model’s capability to use probabilistic rules for breaking of analyte-to-cyclodextrin complexes that were correlated to published experimentally determined equilibrium constants. The model was further expanded to predict the strength of interactions between enantiomer pairs to beta-cyclodextrin and their potential separation. The model accurately predicted the order of strength for six enantiomer pairs. To truly predict chromatographic separation of enantiomers, the model was expanded from one-to-one interactions between enantiomers and beta-cyclodextrin to a larger modeled chromatographic scale. At this scale enantiomer separation was modeled and evaluated for peak resolution and selectivity while varying column temperature, mobile phase pH and flow, and injection volumes. All results agreed well with published laboratory results. With the cost of research and development increasing, ongoing budget cuts, and the rush to get products to market first, an analytical model that can run multiple chromatographic simulations in minutes versus days could prove a valuable tool to many industries.

A ifosfamida é um pró-fármaco que apresenta um átomo de fósforo quiral, disponível na clínica como mistura racêmica dos enantiômeros(+)-(R)-ifosfamida e (-)-(S)-ifosfamida para a utilização na quimioterapia. O objetivo do presente estudo foi o de avaliar a disposição cinética dos enantiômeros da ifosfamida em plasma de pacientes portadoras de câncer de colo do útero. As pacientes investigadas (n=6) receberam 2,5 g/m2 de ifosfamida racêmica administrada como infusão de 12 horas, sendo coletadas amostras de sangue imediatamente antes da administração e em 6, 10, 11, 12, 13, 14, 16, 18, 20 e 22 horas após a administração do fármaco. Os enantiômeros da ifosfamida foram quantificados por LC-MS/MS, sendo separados na coluna OD-R em aproximadamente 14 min empregando como fase móvel mistura de acetonitrila e água (20:80) adicionada de 0,2% de ácido fórmico. O método é linear no intervalo de 1-100 ?g de cada enantiômero/mL de plasma a partir de extrações de alíquotas de 25 ?L de plasma, compatíveis com a aplicação em farmacocinética de infusão de curta duração da ifosfamida em pacientes com câncer de colo do útero.A disposição cinética da ifosfamidaéenantiosseletiva, com observação de maiores valores de AUC (437,31 vs349,18 h.?g/mL) e menores valores de clearance(4,17 vs5,22 L/h) para o enantiômero(+)-(R)-ifosfamida. / The prodrugifosfamide has a chiral phosphorus atom, and is available clinically as a racemic mixture of the enantiomers (+)-(R)-ifosfamide and (-)-(S)-ifosfamide for use in chemotherapy. The aim of this study was to evaluate the kinetic disposition of the enantiomers of ifosfamide in plasma of patients with cancer of the cervix. The investigated patients (n = 6) received 2.5 g/m2 of racemic ifosfamide administered as infusion of 12 hours and blood samples were collected immediately before administration and at 6, 10, 11, 12, 13, 14, 16, 18, 20 and 22 hours after drug administration. The enantiomers of ifosfamide were quantified by LC-MS/MS and were separated in an OD-R column in about 14 min using as mobile phase a mixture of acetonitrile and water (20:80) plus 0.2% of formic acid. The method is linear within the range of 1-100 mg of each enantiomer/mL of plasma from extractions of 25 mL aliquots of plasma, suitable for the application in pharmacokinetics of short duration infusion of ifosfamide in patients with cervical cancer. The kineticdisposition of ifosfamide is enantioselective, with observation of higher values of AUC (437.31 vs 349.18 h.?g/mL) and lower values of clearance (4.17 vs 5.22 L/h) for the enantiomer (+)-(R)-ifosfamide.

The first three, pure, single-isomer, 6-O-sulfo a-cyclodextrins, the sodium salts of hexakis(6-O-sulfo)-a-CD (HxS), hexakis(2,3-di-O-methyl-6-O-sulfo)-a-cyclodextrin (HxDMS) and hexakis(2,3-di-O-acetyl-6-O-sulfo)-a-cyclodextrin (HxDAS) have been synthesized, analytically characterized and utilized as chiral resolving agents in capillary electrophoresis. The purity of each synthetic intermediate and of the final product was determined by HPLC-ELSD and indirect UV-detection capillary electrophoresis. The structural identity of each intermediate and final product was verified by 1D and 2D NMR, and mass spectrometry.HxS, HxDMS and HxDAS have been used to separate a series of neutral, basic, ampholytic and acidic enantiomers in pH 2.5 and pH 9.5 aqueous and acidic methanol background electrolytes using capillary electrophoresis. Rapid separations with satisfactory peak resolution values were obtained for most of the analytes, indicating that HxS, HxDAS and HxDMS can serve as chiral resolving agent for a wide range of analytes. The observed separation patterns follow the predictions of the CHArged Resolving agent Migration (CHARM) model. The separation patterns observed with HxS, HxDAS and HxDMS as chiral resolving agent were compared with those of (1) b-cyclodextrin analogues, such as, heptakis(6-O-sulfo)-b-cyclodextrin (HS), heptakis(2,3-di-O-acetyl-6-O-sulfo)-b-cyclodextrin (HDAS) and heptakis(2,3-di-O-methyl-6-O-sulfo)-b-cyclodextrin (HDMS); (2) g-cyclodextrin analogues, such as, octakis(6-O-sulfo)-g-cyclodextrin (OS), octakis(2,3-di-O-acetyl-6-Osulfo)- g-cyclodextrin (ODAS) and octakis(2,3-di-O-methyl-6-O-sulfo)-g-cyclodextrin (ODMS). The effects of the structure of the analytes, and those of the pH and the solvent of the background electrolyte were also studied.